Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)

Aldo P. Maggioni, Roberto Latini, Peter E. Carson, Steven N. Singh, Simona Barlera, Robert Glazer, Serge Masson, Elisabetta Cerè, Gianni Tognoni, Jay N. Cohn

Research output: Contribution to journalArticle

343 Citations (Scopus)

Abstract

Background: Atrial fibrillation (AF) in heart failure (HF) is generally considered a negative prognostic factor. Recent studies indicate that the incidence of AF might be decreased by renin angiotensin aldosterone system inhibitors. The identification of a treatment to prevent its occurrence is likely to improve patients outcome. The aims of these subanalyses of Val-HeFT were to assess (a) the effects of valsartan in the prevention of AF, (b) the independent predictors of this event, and (c) the prognostic role of AF occurrence. Methods and Results: The occurrence of AF was evaluated based on adverse event reports in the patients with HF enrolled in Val-HeFT. Patients were randomized to valsartan or placebo on top of their prescribed treatments for HF. During the mean 23 months of follow-up, AF was reported in 287/4395 patients (6.53%) in sinus rhythm at baseline, of whom 113/2205 (5.12%) were allocated to valsartan and 174/2190 (7.95%) to placebo (P =. 0002). Multivariable analysis showed that brain natriuretic peptide (BNP) levels at baseline above the median value (HR 2.28, 95% CI 1.75-2.98), age over 70 years (HR 1.51, 95% CI 1.17-1.95), male sex (HR 1.53, 95% CI 1.07-2.18), and the valsartan treatment (HR 0.63, 95% CI 0.49-0.81) were independently associated with AF occurrence. Cox multivariable regression analysis showed that occurrence of AF was independently associated with a worse prognosis, with the adjusted hazard risks for all-cause mortality and combined mortality/morbidity of 1.40 (95% CI 1.16-1.58) and 1.38 (95% CI 1.12-1.70), respectively. Conclusions: The results of the present study demonstrate that (a) adding valsartan to prescribed therapy for HF significantly reduces the incidence of AF by 37%; (b) BNP level and advanced age were the strongest independent predictors for AF occurrence; and (c) AF occurrence further worsens the outcome in patients with HF.

Original languageEnglish (US)
Pages (from-to)548-557
Number of pages10
JournalAmerican Heart Journal
Volume149
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Valsartan
Atrial Fibrillation
Heart Failure
Incidence
Brain Natriuretic Peptide
Placebos

Cite this

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure : Results from the Valsartan Heart Failure Trial (Val-HeFT). / Maggioni, Aldo P.; Latini, Roberto; Carson, Peter E.; Singh, Steven N.; Barlera, Simona; Glazer, Robert; Masson, Serge; Cerè, Elisabetta; Tognoni, Gianni; Cohn, Jay N.

In: American Heart Journal, Vol. 149, No. 3, 03.2005, p. 548-557.

Research output: Contribution to journalArticle

Maggioni, Aldo P. ; Latini, Roberto ; Carson, Peter E. ; Singh, Steven N. ; Barlera, Simona ; Glazer, Robert ; Masson, Serge ; Cerè, Elisabetta ; Tognoni, Gianni ; Cohn, Jay N. / Valsartan reduces the incidence of atrial fibrillation in patients with heart failure : Results from the Valsartan Heart Failure Trial (Val-HeFT). In: American Heart Journal. 2005 ; Vol. 149, No. 3. pp. 548-557.
@article{9fb843e86b274ee39f22a0ee1ee1223f,
title = "Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)",
abstract = "Background: Atrial fibrillation (AF) in heart failure (HF) is generally considered a negative prognostic factor. Recent studies indicate that the incidence of AF might be decreased by renin angiotensin aldosterone system inhibitors. The identification of a treatment to prevent its occurrence is likely to improve patients outcome. The aims of these subanalyses of Val-HeFT were to assess (a) the effects of valsartan in the prevention of AF, (b) the independent predictors of this event, and (c) the prognostic role of AF occurrence. Methods and Results: The occurrence of AF was evaluated based on adverse event reports in the patients with HF enrolled in Val-HeFT. Patients were randomized to valsartan or placebo on top of their prescribed treatments for HF. During the mean 23 months of follow-up, AF was reported in 287/4395 patients (6.53{\%}) in sinus rhythm at baseline, of whom 113/2205 (5.12{\%}) were allocated to valsartan and 174/2190 (7.95{\%}) to placebo (P =. 0002). Multivariable analysis showed that brain natriuretic peptide (BNP) levels at baseline above the median value (HR 2.28, 95{\%} CI 1.75-2.98), age over 70 years (HR 1.51, 95{\%} CI 1.17-1.95), male sex (HR 1.53, 95{\%} CI 1.07-2.18), and the valsartan treatment (HR 0.63, 95{\%} CI 0.49-0.81) were independently associated with AF occurrence. Cox multivariable regression analysis showed that occurrence of AF was independently associated with a worse prognosis, with the adjusted hazard risks for all-cause mortality and combined mortality/morbidity of 1.40 (95{\%} CI 1.16-1.58) and 1.38 (95{\%} CI 1.12-1.70), respectively. Conclusions: The results of the present study demonstrate that (a) adding valsartan to prescribed therapy for HF significantly reduces the incidence of AF by 37{\%}; (b) BNP level and advanced age were the strongest independent predictors for AF occurrence; and (c) AF occurrence further worsens the outcome in patients with HF.",
author = "Maggioni, {Aldo P.} and Roberto Latini and Carson, {Peter E.} and Singh, {Steven N.} and Simona Barlera and Robert Glazer and Serge Masson and Elisabetta Cer{\`e} and Gianni Tognoni and Cohn, {Jay N.}",
year = "2005",
month = "3",
doi = "10.1016/j.ahj.2004.09.033",
language = "English (US)",
volume = "149",
pages = "548--557",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Valsartan reduces the incidence of atrial fibrillation in patients with heart failure

T2 - Results from the Valsartan Heart Failure Trial (Val-HeFT)

AU - Maggioni, Aldo P.

AU - Latini, Roberto

AU - Carson, Peter E.

AU - Singh, Steven N.

AU - Barlera, Simona

AU - Glazer, Robert

AU - Masson, Serge

AU - Cerè, Elisabetta

AU - Tognoni, Gianni

AU - Cohn, Jay N.

PY - 2005/3

Y1 - 2005/3

N2 - Background: Atrial fibrillation (AF) in heart failure (HF) is generally considered a negative prognostic factor. Recent studies indicate that the incidence of AF might be decreased by renin angiotensin aldosterone system inhibitors. The identification of a treatment to prevent its occurrence is likely to improve patients outcome. The aims of these subanalyses of Val-HeFT were to assess (a) the effects of valsartan in the prevention of AF, (b) the independent predictors of this event, and (c) the prognostic role of AF occurrence. Methods and Results: The occurrence of AF was evaluated based on adverse event reports in the patients with HF enrolled in Val-HeFT. Patients were randomized to valsartan or placebo on top of their prescribed treatments for HF. During the mean 23 months of follow-up, AF was reported in 287/4395 patients (6.53%) in sinus rhythm at baseline, of whom 113/2205 (5.12%) were allocated to valsartan and 174/2190 (7.95%) to placebo (P =. 0002). Multivariable analysis showed that brain natriuretic peptide (BNP) levels at baseline above the median value (HR 2.28, 95% CI 1.75-2.98), age over 70 years (HR 1.51, 95% CI 1.17-1.95), male sex (HR 1.53, 95% CI 1.07-2.18), and the valsartan treatment (HR 0.63, 95% CI 0.49-0.81) were independently associated with AF occurrence. Cox multivariable regression analysis showed that occurrence of AF was independently associated with a worse prognosis, with the adjusted hazard risks for all-cause mortality and combined mortality/morbidity of 1.40 (95% CI 1.16-1.58) and 1.38 (95% CI 1.12-1.70), respectively. Conclusions: The results of the present study demonstrate that (a) adding valsartan to prescribed therapy for HF significantly reduces the incidence of AF by 37%; (b) BNP level and advanced age were the strongest independent predictors for AF occurrence; and (c) AF occurrence further worsens the outcome in patients with HF.

AB - Background: Atrial fibrillation (AF) in heart failure (HF) is generally considered a negative prognostic factor. Recent studies indicate that the incidence of AF might be decreased by renin angiotensin aldosterone system inhibitors. The identification of a treatment to prevent its occurrence is likely to improve patients outcome. The aims of these subanalyses of Val-HeFT were to assess (a) the effects of valsartan in the prevention of AF, (b) the independent predictors of this event, and (c) the prognostic role of AF occurrence. Methods and Results: The occurrence of AF was evaluated based on adverse event reports in the patients with HF enrolled in Val-HeFT. Patients were randomized to valsartan or placebo on top of their prescribed treatments for HF. During the mean 23 months of follow-up, AF was reported in 287/4395 patients (6.53%) in sinus rhythm at baseline, of whom 113/2205 (5.12%) were allocated to valsartan and 174/2190 (7.95%) to placebo (P =. 0002). Multivariable analysis showed that brain natriuretic peptide (BNP) levels at baseline above the median value (HR 2.28, 95% CI 1.75-2.98), age over 70 years (HR 1.51, 95% CI 1.17-1.95), male sex (HR 1.53, 95% CI 1.07-2.18), and the valsartan treatment (HR 0.63, 95% CI 0.49-0.81) were independently associated with AF occurrence. Cox multivariable regression analysis showed that occurrence of AF was independently associated with a worse prognosis, with the adjusted hazard risks for all-cause mortality and combined mortality/morbidity of 1.40 (95% CI 1.16-1.58) and 1.38 (95% CI 1.12-1.70), respectively. Conclusions: The results of the present study demonstrate that (a) adding valsartan to prescribed therapy for HF significantly reduces the incidence of AF by 37%; (b) BNP level and advanced age were the strongest independent predictors for AF occurrence; and (c) AF occurrence further worsens the outcome in patients with HF.

UR - http://www.scopus.com/inward/record.url?scp=17844369714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844369714&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2004.09.033

DO - 10.1016/j.ahj.2004.09.033

M3 - Article

C2 - 15864246

AN - SCOPUS:17844369714

VL - 149

SP - 548

EP - 557

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -